A Practical Framework for Managing Pharmacy Spend

Amir Borde

Key Takeaways

Pharmacy cost management should balance financial goals with clinical appropriateness, patient access, safety, and continuity of care.

Prescription-claims analysis can identify high-cost patterns, but every potential medication change requires appropriate clinical review.

Physician engagement is most useful when recommendations include relevant formulary information, potential alternatives, and patient-specific context without disrupting the prescriber’s normal workflow.

FDA-approved generic medicines provide the same clinical benefits and risks as their brand-name counterparts, but generic substitution is different from switching to another drug in the same therapeutic category.

Biosimilars may create additional options for certain biologic medicines. Formulary status, clinical circumstances, and applicable substitution rules should be reviewed before a change.

PBM contract terms, rebates, fees, utilization controls, and member cost sharing all affect the actual cost of a pharmacy benefit.

Success should be measured through validated claims data and patient-centered outcomes, not solely through the number of recommendations issued.

Involving Prescribers in Pharmacy Cost Management

Give Physicians Useful Information at the Point of Decision

A prescribing physician may not have access to the patient’s current pharmacy benefit information while selecting a medication. Formularies, preferred products, prior-authorization requirements, and member costs can vary among plans and may change during the year.

Giving the prescriber timely information can help identify an appropriate covered option before the patient reaches the pharmacy. The recommendation should explain why the alternative is being presented and provide enough clinical and benefit information for the physician to evaluate it.

A cost-saving opportunity does not automatically mean that a medication should be changed. The physician may know about previous treatment failures, allergies, adverse reactions, or other factors that are not visible in pharmacy claims.

Organizations evaluating pharmacy cost reduction strategies can consider systems that route recommendations through the prescribing physician. RazorMetrics describes its model as physician-directed: its platform identifies potential opportunities and sends them to the prescriber, who approves or declines the proposed change.

This approach keeps the clinical decision with the healthcare professional responsible for the patient’s treatment. It also creates an opportunity to document why a recommendation was accepted or rejected.

Useful communications may include:

  • The current prescription
  • The proposed alternative
  • Formulary and coverage information
  • Estimated plan and member costs
  • Relevant medication history
  • The reason for the recommendation
  • A method for approving or declining the change

Recommendations should be concise enough to review without obscuring important clinical details.

Fit Technology Into the Existing Clinical Workflow

A separate portal or application may add work for a physician who already manages electronic health records, pharmacy messages, prior authorizations, and patient communications.

A physician-directed platform should reach the prescriber through a familiar workflow whenever possible. It should also allow the prescriber to reject a recommendation without creating unnecessary administrative steps.

RazorMetrics states that its RazorCodex platform analyzes pharmacy information, identifies potential savings opportunities, and routes recommendations through existing prescriber workflows. The company says the process does not require physicians or members to download a separate application.

The company describes its approach to technology with the following statement:

“We augment clinical wisdom with well-timed AI.”
Source: RazorMetrics

Artificial intelligence and automated rules may help review large claims populations. They should not be treated as independent prescribers. The technology can surface a potential opportunity, while the licensed clinician evaluates whether the change is appropriate for the patient.

Organizations assessing a platform should ask:

  • Which data sources are analyzed?
  • How are clinical rules reviewed and updated?
  • How are incorrect recommendations identified?
  • What information does the prescriber receive?
  • How are accepted changes communicated to the pharmacy and member?
  • How are declined recommendations recorded?
  • What security and privacy controls apply?

Implementation should also include a process for handling incomplete records. Pharmacy claims may not show over-the-counter products, samples, cash purchases, or every clinical reason behind a prescription.

Using Data to Identify Actionable Opportunities

Examine Drug Spending in Its Proper Context

Pharmacy claims can reveal where spending is concentrated and how utilization changes over time. Useful analyses may identify high-cost drug categories, unexpected increases, duplicate therapies, nonpreferred products, or medications with lower-cost alternatives.

The analysis should not assume that every expensive prescription is inefficient. A high-cost medicine may be clinically necessary and appropriate for a particular patient.

Data should be examined in the context of:

  • Covered population changes
  • New drug approvals
  • Formulary revisions
  • Manufacturer price changes
  • Specialty-drug utilization
  • Rebate arrangements
  • Patient cost sharing
  • Changes in disease prevalence

A rise in gross pharmacy spending may have several causes. It could reflect higher prices, increased utilization, new members, or appropriate treatment of previously unmet needs.

Organizations should also distinguish gross spending from net spending. Rebates, administrative fees, guarantees, and other contract terms can materially affect the plan’s final cost.

Analytics may help prioritize opportunities for review. The result should be a manageable list of recommendations that can be examined for clinical relevance and financial value.

Use Benchmarks Carefully

Benchmarking can help a plan understand whether its utilization differs from a comparable population. A useful comparison should account for population size, age, health status, benefit design, formulary, geographic factors, and the period being measured.

A generic dispensing rate from one plan may not be directly comparable with another if the populations or covered therapies differ. The same problem applies to specialty-drug spending and medication adherence.

Organizations should document:

  • The source of the benchmark
  • The population represented
  • The measurement period
  • The definition of each metric
  • Whether rebates and fees are included
  • How clinical differences were adjusted

Internal trends can sometimes be more informative than a broad industry average. Comparing the same plan across equivalent periods may reveal whether a program changed utilization or net cost.

Benchmarking should be used to identify questions, not to declare automatically that a prescriber or plan is inefficient.

Potential findings should be reviewed by people with relevant pharmacy, clinical, benefits, and financial expertise before policy changes are made.

Evaluating Medication and Benefit Options

Distinguish Generics, Therapeutic Alternatives, and Biosimilars

Medication substitutions are not all the same.

An FDA-approved generic medicine has the same active ingredient, strength, dosage form, route of administration, and expected clinical effect as its brand-name counterpart. Generics must meet FDA standards for quality and bioequivalence.

The FDA summarizes this clearly:

“Generic medicines work the same as brand-name medicines.”
Source: U.S. Food and Drug Administration

Inactive ingredients and appearance may differ. Patients with tolerability concerns should discuss them with a physician or pharmacist.

A therapeutic alternative is a different medication that may be used for the same or a related condition. It may have a different active ingredient, dosing schedule, side-effect profile, or monitoring requirement. A physician must determine whether it is appropriate for the individual patient.

Biosimilars are highly similar to FDA-approved reference biologics and have no clinically meaningful differences in safety or effectiveness. They are not the same as traditional generic drugs. Pharmacy substitution rules may depend on interchangeability status and state law.

Before recommending a change, an organization should consider:

  • FDA approval and labeling
  • The patient’s diagnosis
  • Previous treatment history
  • Contraindications and interactions
  • Formulary placement
  • Expected member cost
  • Monitoring requirements
  • Applicable substitution rules

Cost is relevant, but it is only one part of the decision.

Understand the Role of the PBM and Other Vendors

A pharmacy benefit manager may negotiate with manufacturers and pharmacies, manage a formulary, operate a pharmacy network, process claims, and administer utilization-management programs.

The financial effect of a PBM arrangement depends on the contract. Rebates, administrative charges, spread pricing, guarantees, specialty-pharmacy terms, and data-access provisions may all affect the plan’s net cost.

RazorMetrics states that it is not a PBM. It operates alongside existing PBM arrangements as an additional cost-containment layer. Its model focuses on identifying medication opportunities and seeking physician approval without replacing the plan’s formulary or pharmacy network.

Plan sponsors should understand how all vendors interact. A recommendation that appears to reduce the ingredient cost could have a different net result after rebates or contract guarantees are considered.

Contract and program reviews may examine:

  • Gross and net drug costs
  • Rebate and fee terms
  • Formulary exclusions
  • Specialty-drug arrangements
  • Pharmacy network pricing
  • Audit rights
  • Data ownership and access
  • Performance guarantees
  • Termination provisions

No vendor should be evaluated only through projected savings. The organization should require clear definitions, transparent measurement methods, and a process for validating results.

Measuring Financial and Clinical Results

Establish Metrics Before the Program Begins

A pharmacy cost-management program should define success before recommendations are issued. Otherwise, it may be difficult to distinguish actual savings from changes that would have occurred without the program.

Financial measures may include:

  • Gross pharmacy spending
  • Net pharmacy spending after rebates and fees
  • Per-member-per-month cost
  • Spending by therapeutic category
  • Cost per prescription
  • Member out-of-pocket cost
  • Specialty-drug spending
  • Validated savings from completed changes

Operational measures can track how the program functions. Examples include physician response, recommendation acceptance, completed prescription changes, reversals, and time from identification to resolution.

Acceptance alone does not establish savings. The new prescription must be issued, filled, and reflected correctly in the claims data. The member may also return to the original medicine later.

A savings methodology should state:

  • The baseline price
  • The comparison period
  • The expected duration of the change
  • Included rebates and fees
  • Adjustments for discontinuation
  • Treatment of prescription reversals
  • Treatment of dosage changes
  • Validation procedures

The organization should also monitor whether member costs changed. A plan-level saving that raises the patient’s out-of-pocket expense may create adherence concerns.

Keep Clinical Oversight Part of Continuous Improvement

Cost-management programs should be reviewed regularly, but there is no universal schedule that suits every organization. High-volume programs may require monthly monitoring, while broader benefit reviews may occur quarterly or annually.

Clinical measures should remain part of the evaluation. Depending on the program, these may include medication adherence, therapy abandonment, adverse-event reports, treatment reversals, or requests to return to the previous medicine.

Deprescribing requires particular caution. It is the planned reduction or discontinuation of a medicine that may no longer be necessary or may create more risk than benefit. It should involve appropriate clinical assessment and follow-up.

Polypharmacy analysis can identify possible duplicate therapies or interaction risks. Claims data alone may not establish that a medicine is unnecessary. The physician needs a complete picture of the patient’s medications and health conditions.

Continuous improvement may involve:

  • Reviewing declined recommendations
  • Correcting outdated formulary information
  • Refining clinical rules
  • Improving prescriber communications
  • Monitoring patient concerns
  • Validating savings calculations
  • Evaluating unintended effects

A program should be willing to stop or revise a recommendation category if it creates confusion, fails to produce validated value, or raises clinical concerns.

Pharmacy cost management works best when analytics support informed decisions instead of replacing them. Financial savings should be pursued through clinically appropriate changes that physicians can evaluate and patients can understand.

FAQ

How should medication recommendations be shared with physicians?

Recommendations should reach physicians through a secure and familiar workflow. They should identify the current medicine, proposed alternative, reason for the recommendation, and relevant benefit information while leaving the final decision with the prescriber.

What role does patient communication play?

Patients should understand any approved medication change, including how to take the new medicine and whom to contact with concerns. Communication can also explain potential cost differences without implying that the lower-cost choice is suitable for every patient.

How do PBMs influence prescription costs?

PBMs may manage formularies, negotiate manufacturer rebates, contract with pharmacy networks, and administer prescription claims. Their effect on net cost depends on the specific contract, fees, rebates, pricing methods, and utilization programs.

Are generics always appropriate substitutes?

An FDA-approved generic is generally considered therapeutically equivalent to its reference brand drug. However, patients should discuss allergies, inactive ingredients, previous reactions, or other concerns with a physician or pharmacist.

Why is benchmarking useful?

Benchmarking can reveal differences in utilization or spending that deserve investigation. Comparisons are most useful when populations, benefit designs, time periods, and metric definitions are sufficiently similar.

What data can identify potential savings opportunities?

Pharmacy claims, eligibility information, formulary data, drug pricing, and transaction history can identify potential opportunities. Clinical context may be needed before any recommendation is acted upon.

How often should a pharmacy cost program be reviewed?

The appropriate schedule depends on program size, claim volume, contract requirements, and risk. Operational metrics may be reviewed monthly or quarterly, with a broader financial and clinical evaluation conducted at least annually.

Which metrics provide the clearest measure of success?

Validated net savings, completed prescription changes, physician response, member cost, adherence, reversals, and relevant clinical outcomes provide a more complete view than recommendation volume alone.

Useful Resources

Share This Article
Amir Borde is the administrator of NewsWorldDaily, a leading online news platform known for its comprehensive coverage of global events. With a strong background in digital media and journalism, Amir plays a pivotal role in shaping the editorial direction and maintaining the site's commitment to accurate, timely reporting.
Leave a comment